Parabilis Medicines (formerly FogPharma) is a clinical-stage oncology company developing novel peptide therapies.

Parabilis Medicines is developing peptide therapies against intracellular targets by leveraging the "stapled peptides" technology discovered by co-founder Greg Verdine. Stapled peptides address the historical challenges of getting peptides into cells. The team is initially focused on colorectal cancer and its lead program targets β-catenin, which is involved in over 20% of all cancers and is an important pathway for cellular stability.